A recent breakthrough in Alzheimer’s research has ignited hope and optimism within the medical community. 'Donanemab' has emerged as a potential game-changer and is being hailed as a "turning point in the fight against Alzheimer's.” But how will this potentially impact other cognitive conditions? Joining Luke O'Neill to discuss this is Professor Marina Lynch, Fellow Emeritus in Physiology at Trinity College Dublin.